Key result
Direct oral anticoagulants were superior to vitamin K antagonists in reducing stroke (RR 0.44; 95% CI 0.24-0.82; p<0.01) and major bleeding in patients with atrial fibrillation and bioprosthetic valves.
Why the study?
The optimal anticoagulation therapy for patients with atrial fibrillation and a history of bioprosthetic valve replacement or repair is not well understood.
Do direct oral anticoagulants reduce stroke, major bleeding, and mortality in patients with atrial fibrillation and bioprosthetic valve replacement compared to vitamin K antagonists?
Meta-Analysis (n=1,911)
Do direct oral anticoagulants reduce stroke, major bleeding, and mortality in patients with atrial fibrillation and bioprosthetic valve replacement compared to vitamin K antagonists?
Relative Risk: 0.44 (95% CI 0.24–0.82)
p-value: p=< 0.01
In patients with atrial fibrillation and bioprosthetic valves, DOACs appear superior to VKAs for reducing stroke and major bleeding without affecting mortality.
OBJECTIVES: This systematic review and meta-analysis compares direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and bioprosthetic valve replacement or repair (BVR). BACKGROUND: The optimal anticoagulation therapy for patients with atrial fibrillation and a history of bioprosthetic valve replacement or repair (BVR) is not well understood. METHODS: We performed a systematic literature review to identify clinical studies that compared anticoagulation therapies for patients with atrial fibrillation and BVR. The primary outcomes of stroke, major bleeding, and mortality were reported as random effects risk ratio (RR) with 95% confidence interval. No prior ethical approval was required since all data is public. RESULTS: Our search yielded 101 potential studies. We included six studies reporting on 1911 patients. There was a lower risk of stroke and major bleeding in patients with atrial fibrillation after BVR treated with DOACs when compared to VKAs with risk ratios of 0.44 (95% CI 0.24-0.82, p < 0.01) and 0.53 (95% CI 0.34-0.83, p < 0.01), respectively. There was no statistically significant difference in mortality between patients with atrial fibrillation after BVR treated with DOACs compared to patients treated with VKAs with a risk ratio of 1.12 (95% CI 0.73-1.74, p = 0.60). CONCLUSION: This systematic review and meta-analysis suggests that DOACs are superior to VKAs with respect to stroke and major bleeding in patients with atrial fibrillation and BVR.
No takes yet. Share an insight, caveat, or question.
Lacy et al. (2021) conducted a meta-analysis in Atrial fibrillation and bioprosthetic valve replacement or repair (n=1,911). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Stroke (RR 0.44, 95% CI 0.24-0.82, p=< 0.01). Direct oral anticoagulants were superior to vitamin K antagonists in reducing stroke (RR 0.44; 95% CI 0.24-0.82; p<0.01) and major bleeding in patients with atrial fibrillation and bioprosthetic valves.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: